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Abstract. Transanai endoscopic microsurgery (TEM) allows local exci- 
sion of rectal tumors located 4 to 18 cm above the anal verge. The 
technique is not yet generally established because of the necessary special 
instrumentation and tools, the unusual technical aspects of the approach, 
and the stringent patient selection criteria. The aim of this prospective, 
descriptive study was to analyze the currently accepted indications for 
TEM and to evaluate the use of this procedure for treating rectal cancer. 
Over a 4-year period 50 patients aged 31 to 86 years (mean 64 years) 
underwent TEM for treatment of rectal tumors located 12 cm above the 
anal verge (range 4-18 cm). The local complication rate was 4%. Alto- 
gether, 76% of lesions were benign, and 24% were T1 and T2 tumors. Of 
12 cancer cases, 4 required reoperation by total mesorectal resection; the 
other 8 are currently under follow-up management. Over the follow-up 
period of 30.6 months (range 11-54 months) the recurrence rate of T1 
tumors was 8.3%. TEM is a minimally invasive surgical technique that 
may benefit a small, specific population of patients with rectal tumors. 
Compared with conventional transanai resection, TEM provides superior 
exposure of tumors higher up in the rectum (i.e., up to 18 cm from the 
anal verge). The greater precision of resection combined with low mor- 
bidity (I0%, relative to that of anterior resection) and short duration of 
hospitalization (5.5 days) make this technique a reliable and in some 
cases more effective surgical approach than laparotomy and low anterior 
resection. 
The introduction of transanal endoscopic microsurgcry (TEM) by 
Buess et al. in 1983 realized an interesting technical advance in 
localized surgical treatment of rectal tumors [1]. TEM is a mini- 
mally invasive technique that allows precise resection of tumors 
located 2 to t8 cm from the anal verge using an operative micro- 
scope. Thus laparotomy is no longer the only option for managing 
such cases. However, the number of patients treated by TEM by 
Buess et al. during the 15 years since its introduction totaled only 
500 [2], so the worldwide experience is limited. Reasons may 
include the high cost of TEM equipment (up to $80,000), a small 
candidate pool, the stringent criteria for patient selection and 
indications for the procedure [3], and a highly demanding surgical 
technique that requires pecialized training [3]. 
To date, there are only 109 publications on TEM listed by 
Medline. Most of these published series report the experience of 
Buess and his current and former staff members, with only a few 
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reports on the results obtained at other medical centers in Europe 
(Italy, United Kingdom), the United States, and Japan. Thus the 
reliability of this new method has been demonstrated primarily by 
its inventor, and it must now be evaluated by the broader surgical 
community, especially given the current controversy surrounding 
localized management of rectal cancer [4, 5]. The present study 
reports the experience of a department of general surgery at a 
university hospital, with the goals of analyzing the currently ac- 
cepted indications for TEM and evaluating the use of this proce- 
dure for treating rectal cancer. 
Patients, Materials, Methods 
Between January 1995 and September 1999, all patients with 
rectal tumors were examined in our interdisciplinary coloproctol- 
ogy consultation practice. Following clinical examination, a biopsy 
was obtained in all patients, and endorectal sonography was per- 
formed using a 360-degree endoprobe with an inflatable balloon 
at a frequency of 7 MHz to diagnose possible wall infiltration. This 
endosonographic technique has approximately 90% diagnostic 
accuracy. [6]. Simultaneously, we tested the integrity of sphincter 
function and assessed patient continence using the Kirwan-Parks 
classification system [7]. Anal manometry was performed only in 
cases of prolonged postoperative incontinence. 
Preoperative assessment tostage and grade the type and sever- 
ity of tumor resulted in two patient groups: The largest group had 
benign rectal tumor, and the smallest group had proven rectal 
cancer. Benign tumor and low risk rectal cancer were considered 
for TEM resection. Low risk rectal cancer was defined as a well or 
moderately differentiated (G1, G2) T1 tumor without lym- 
phangiosis carcinomatosa [8]. All other types of cancer were 
excluded. Indications for TEM were defined as: (i) a benign 
tumor of any type > 2 cm in diameter; (2) adenoma recurrence; 
(3) low risk rectal cancer; and (4) rectal stenosis after fistula or 
anastomosis. 
Tumors located 2 to 18 cm from the anal verge were treated by 
TEM. Tumors 2 to 4 cm from the a~al verge were considered 
inappropriate for TEM because this setting prohibited proper 
introduction of the 40 mm operating microscope. These patients 
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underwent conventional transanal surgical treatment using the 
Lone Star Retractor (Lone Star Medical Product, Houston, TX, 
USA) and were excluded from the study. 
TEM Technique 
The bowel was prepared as for a formal laparotomy by lavage over 
4 hours with 3 to 4 liters of polyethylene glycol solution. Antibiotic 
prophylaxis for gram-negative and anaerobic strains was given at 
the time of anesthetic induction. Following the technique de- 
scribed by Buess et al. [1, 9], we used an operative rectoscope of 
40 mm diameter and 120 or 200 mm length, with a sixfold mag- 
nified stereoscopic view. The tip of the rectoscope is beveled 
downward. The patient's position for surgery therefore depends 
on the anteroposterior and lateral orientation of the tumor. 
To visualize the anatomic relation between tumor and healthy 
mucosa, CO2 is insufflated to enlarge the intrarectal space and 
facilitate precise resection. This requires use of a combination 
suction-insufflation endosurgical unit to ensure constant, high 
flow of gas and to evacuate the smoke due to coagulation. The 
operation itself was performed as described originally by Buess et 
al. [1, 9]. The use of a multifunctional instrument (suction/irriga- 
tion, coagulation, cutting) (ERBE, Elektromedizin GmbH, Tii- 
bingen, Germany) eased and sped up the procedure. 
To optimize access to the entire tumor, the rectoscope orien- 
tation must be changed frequently to compensate for the limited 
operating field and length of the surgical instruments. Finally, the 
resection specimen is affixed to a preparation plate to allow the 
pathologists a precise description of the resection margin in 5 ram 
of healthy tissue 
Postoperatively, patients are allowed to sit and walk as soon as 
they are fully recovered from anesthesia. A liquid diet is main- 
tained for 24 hours, and patients are discharged on postoperative 
day 2 or 3. Initial clinical follow-up occurs at 6 weeks postopera- 
tively and the final clinical examination, including endorectal 
sonography, at 3 months. 
Data Analysis 
Patient data were prospectively collected on a personal computer 
and managed using Microsoft Excel. Descriptive statistics were 
used, and results are expressed as the absolute value, percent, 
mean, and range. 
Results 
Over the 4-year period of study, 50 patients atisfied the indica- 
tions for TEM and were included in the study. Of these, 19 were 
female and 31 male, with a median age of 65 years (range 31-86 
years). All underwent surgery, for a tumor located a mean 12 cm 
from the anal verge (range 4-18 cm). Rectal blood loss was the 
leading symptom in 31 cases (66%). The tumor was found inci- 
dentally by routine examination i  5 cases (10%). All other pa- 
tients presented with loss of mucus or nonspecific pain during 
defecation. 
Preoperative endorectal sonography correctly staged the tumor 
in 45 cases (90%). "Overstaging" occurred in 3 cases (6%) and 
"understaging'" in 2 cases (4%). 
Of the 51) procedures, 31 were performed in the lateral position 
(62%). 13 in the "jackknife prone" position (26%), and 6 in the 
Table l. TEM resections. 
Diagnosis (n = 50) No. % 
Villous adenoma 35 70 
Rectal cancer 12 24 
Carcinoid tumor 1 2 
Stenosis 1 2 
Recurrence (adenoma) 1 2 
TEM: transanal endoscopic microsurgical excision. 
"lithotomy" position (t2%). Forty-two cases were performed un- 
der general anesthesia (84%) and 8 under regional anesthesia 
(16%). The average operating time was 117 minutes (range 45- 
240 minutes). 
Full-thickness resection (mucosa nd serosa until perireetal fat) 
was performed in 45 cases (90%) and mucosectomy in 5 cases 
(10%). We decided to convert one case intraoperatively to lapa- 
rotomy to avoid any oncologic risk due to rectal wall infiltration. 
This case was not excluded from the TEM data analysis. There 
were two cases of inadvertent peritoneal entry (2/50, 4%) associ- 
ated with resection of tumors located 16 and 18 cm from the anal 
verge, respectively. One case required laparotomy, and the other 
resolved following a conservative 4-week course of treatment with 
protective loop sigmoidostomy. In addition, there were five sys- 
temic complications (5/50, 10%): four minor problems (e.g., urine 
infection) and one major problem (myocardial infarction). There 
was no mortality. 
Postoperative pain was rare, and the median hospitalization was 
5.5 days (range 2-20 days). The patient who sustained a myocar- 
dial infarction remained hospitalized for 20 days owing to the 
development of pneumonia. Reoperation was required in 5 of 50 
cases (10%), involving laparotomy and total mesorectal resection 
[10] for four cases of cancer and anterior esection for one case of 
rectal wall perforation and peritoneal entry followed by abscess. 
Assessment of sphincter function revealed one 85-year-old pa- 
tient who was incontinent (grade III, liquids and solids) preoper- 
atively and remained so postoperatively. Six patients (12%) who 
were initially continent developed incontinence (grade II, liquids 
and gas) during the first 2 weeks after operation. Clinical fol- 
low-up at 3 months showed that all six patients had fully recov- 
ered. Manometric studies were not performed in these cases. 
Histolo, W 
Lesions were benign in 38 cases (76%) and malignant in 12 cases 
(24%). The histologic diagnosis indicated 32 villous adenomas 
(64%). 9 T1 (18%) and 3 T2 (6%) rectal tumors, 3 polyps (6%), 
I carcinoid (2%), 1 recurrent polyp (2%), and 1 rectal stenosis 
after a high fistula (2%). The results are summarized in Table 1 
with the tumor grading and additional treatment in Table 2. A 
diagnosis of cancer was known in eight cases, suspected in two 
cases, and surprising in two other cases. Four cases of cancer (two 
T2 lesions and two T1 tumors) required reoperation by total 
mesorectal resection (Table 2). 
The T1 tumors were resected by TEM with a safe margin of at 
least 5 mm and are under follow-up management. One 85-year- 
old patient with a T2 tumor refused additional treatment by 
laparotomy or radiotherapy and died of concurrent disease 6 
months postoperatively. 
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Table 2. Cancers resected by TENt (n = 12). 
Stage Grade Treatment 
9 pTI i GI, 6 G2 Follow-up (*~ = 7) 
I G2 Adjuvant herapy' (n = 1) 
1 G3 Total mesorectal resection (n = l) 
3 pT2 3 G2 Total mesorectal resection (n = 2) 
Folk)w-up (patient in poor condition) (n = 1) 
Recurrence rate at 30 months was 8.3%. 
Over the follow-up period of 30.6 months (range 11-54 months 
the recurrence rate of T1 tumor was 8.3%; 14 months after TEM 
resection we detected one case of local recurrence. This patient 
was consequently treated by laparotomy and total mesorectal 
resection and is now under follow-up management. 
Discussion 
As minimally invasive surgical technique, TEM may benefit a 
small, specific population of patients diagnosed with rectal tu- 
mors. It offers the promise of localized treatment of these tumors, 
with relatively few complications and rare mortality. However, 
experience with TEM has been limited primarily to those who 
developed the technique and only a few others, making it neces- 
sary to reexamine functional outcome based on current indica- 
tions and criteria for patient selection for this procedure. 
Our results with TEM indicate that this technique is reproduc- 
ible after surgical training, and that there is a clear benefit for the 
patients with minimal complications, avoiding laparotomy with 
anterior ectum resection. Because they are based on currently 
published indications and criteria for patient selection, our find- 
ings suggest hat these standards remain adequate for identifying 
appropriate surgical candidates for TEM. We are not associated 
with the developers of TEM, so our results provide an indepen- 
dent perspective on the value of the technique. However, our 
series is small and nonrandomized, making larger additional pro- 
spective and randomized studies essential to confirm the true 
value of TEM for treatment of early rectal cancer. 
The TEM technique distinguishes itself from other endoscopic 
or laparoscopic procedures in various ways. (1) It uses a magnified 
binocular stereoscopic device. Compared with the view obtained 
with monocular instruments or video cameras, the view of the 
operating field obtained with TEM provides a depth of field of 
extremely good quality. (2) Surgical instruments are inserted and 
moved in parallel planes unlike taparoscopy, necessitating special- 
ized training and skill to achieve full tumor exposure. (3) Costly 
equipment (about $80,000) is required. The cost of TEM equip- 
ment, combined with the relatively low incidence of the patholo- 
gies for which this procedure is indicated, have limited worldwide 
experience with this technique to a few surgical teams. 
One clear advantage of TEM is an uneventful postoperative 
course. The postoperative analgesic requirement is slight, gener- 
ally limited to a few doses of paracetamol [ l]. Moreover, the 
duration of hospitalization (5.7 days for TEM versus 14.5 days, 
p < 0.0001) [11] and the complication rate (21% versus 35%) [ l l ]  
ar e significantly lower than those reported for low anterior esec- 
tion. Overall, the localized complication rate associated with 
transanal resection lies between 4.0% and 8.3% of cases [2, 12] 
and that for systemic omplications between 14% and 21% (Table 
Table 3. TEM complication rate: review of the relevant literature. 
Year No. Complications (%) Reference 
t996 3{3 4,5 13 
~996 50 20.6 (systemic) 1I 
1996 100 4.0 I4 
1996 153 20.0 (systemic) 15 
1997 27 4.0 16 
1997 423 8.3 2 
1998 226 4.1 17 
t998 46 2.3 18 
1998 73 5.O 19 
1999 50 4.0 Present study 
3) [11, 15, 20]. The results in our patients are comparable (i.e., a 
hospital stay of 5.5 days and localized and systemic omplication 
rates of 4% and 10%, respectively, with no mortality). In fact, 
mortality is rare: Of 109 publications describing the worldwide 
experience of about 3000 TEM cases (Table 3), only one German 
study reported a fatality: a unique, lethal complication of retro- 
peritoneal phlegmon after TEM resection of an adenoma located 
7 cm from the anal verge in a 55-year-old patient who died in 
septic shock after 28 days [21]. 
Effect on Sphincter Function 
It is surprising that prolonged anal dilatation with 4 cm diameter 
(the operative rectoscope) induces few sphincter function prob- 
lems. We observed only postoperative transitory grade II incon- 
tinence in 12% of our patients, with full postoperative r covery 
after 3 months (excluding one elderly patient with chronic incon- 
tinence that did not resolve with surgery). Because this duration of 
incontinence was comparable to that already reported [22-24], we 
did not conduct manometric studies. However, existing manomet- 
ric analyses of the effects of anal dilatation indicated a decrease in 
sphincter tonus ranging from 25% to 37% of preoperative sphinc- 
ter pressure, with complete recovery to clinical continence within 
6 to 16 weeks postoperatively [22-24]. 
bMications ]'or TEM 
The ideal indications for TEM are all types of adenoma located 4 
to 18 cm of the anal verge that cannot be treated by colonoscopy. 
Ideal tumor size ranges in diameter from 20 mm to three-fourths 
of the lumen circumference. A full-thickness resection is recom- 
mended to ensure an appropriate margin of safety. In addition, 
this procedure is technically easier to perform than mucosectomy 
and decreases the risk of missing a small rectal cancer that may be 
located inside the villous adenoma. Such "in situ" cancers have 
been reported in up to 31% of cases [25]. Because the rectal wall 
is sutured after full-thickness resection, removal of a large seg- 
ment of the rectum is not a high risk procedure based on the low 
morbidity reported in the literature (Table 3) and in our own 
series. 
Rectal Cancer. Treatment of rectal cancer by TEM is generally 
accepted for T1 low risk cancer [2]. The recurrence rate following 
this application lies between 4% and 8% [2, 18, 19, 26] compared 
with a local recurrence rate of up to 30% for T1 high risk cancer 
[27]. Patient selection is therefore crucial to good local and on- 
cologic results. 
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Other b~dications. The following indications are rather anecdotal 
but are mentioned for complete information. TEM may be a 
suitable method for resecting stenoses 5 to t5 cm from the dentate 
line (e.g., inflammatory stenosis after a high fistula, as in our 
experience, or colorectal anastomotic stenosis, as described in 
Japan [28]). Other indications, such as transanal rectopexy origi- 
nally proposed by Buess, no longer appears in the literature and 
there are no subsequent reports [29], suggesting that this indica- 
tion is not to be recommended. 
Transcutaneous application of TEM to treat early gastric can- 
cer was first described in 1997 [30]. However, no follow-up has 
been reported, making even a preliminary conclusion question- 
able. 
Patient Selection 
Careful patient selection is crucial to TEM outcome. Preoperative 
staging must be precise. Specifically, a specimen should be avail- 
able for histology, and the tumor should be visualized with the 
rigid rectoscope to determine its distance from the dentate line 
and localize it precisely in the quadrant. Endorectal sonography 
should be performed to assess eventual wall infiltration. Such 
precise staging is reportedly possible with an accuracy of up to 
90% [6, 31]. In the present study, preoperative staging was correct 
in 90% of cases (n = 45 patients), resulted in an overestimate of
tumor severity in 6% (n = 3) and an underestimate in 4% (n = 2). 
Incorrect estimation isa known phenomenon that depends on the 
accuracy of endoluminal sonography, which is examiner-depen- 
dent (learning curve) and described in up to I0% of the cases [6, 
31]. Only one procedure had to be converted to laparotomy 
during the primary operatio n owing to underestimated lesion 
severity, and it occurred early in our experience with the tech- 
nique. 
Limitations of TEM for Treatment of Cancer 
The primary factor limiting the effectiveness of local treatment of 
early rectal cancer is lymph node invasion. The lymph node 
metastasis rate of T1 rectal tumors is between 0% and 15.4%, 
depending on tumor grading [27, 32, 33]. Age less than 45 years is 
recognized as a significant risk factor for such metastasis [33]. Our 
population and those in many other studies have a reported age 
range of 31 to 86 years (median 65 years), suggesting the potential 
presence of high risk. 
Local excision appears to offer a significant advantage. The rate 
of recurrence for T1 tumors resected by TEM lies between 3.8% 
and 8.0% at 13 months' follow-up [18, 19, 26] compared with a 
recurrence rate of 23.0% after conventional transanal surgery 
[34]. If it is unclear that the TEM resection was radical, it is 
essential (and recommended) that an anterior esection be sub- 
sequently performed. This was the decision made in 12% of cases 
in our present series and in 21.4% of cases in the largest series 
reported by Buess's group [2]. In a series of 113 patients, Buess et 
at. found 5 residual tumors among a subset of 39 patients (12.8%) 
who underwent an anterior esection immediately after TEM. The 
tymphadenectomy was negative in all cases for T1 tumor and 
positive in 23.3% of those with T2 and T3 tumors. In the entire 
series, the failure rate for 81 T1 tumors treated only by TEM was 
4.5% (n = 4), and for 22 T1 tumors requiring anterior esection 
following TEM it was 13.6% (n = 3). The interpretation of these 
results is limited because the difference in the failure rates is not 
significant; moreover, the study was retrospective and may reflect 
a negative selection [2]. 
To date, the only published prospective, randomized study 
comprised 52 patients with T1 tumors treated by TEM or anterior 
resection [11]. There were no significant differences in group 
outcome: The 5-year survival was 96%; the local recurrence rate 
was 4.1% for TEM and 0% for anterior esection; and the me- 
tastasis rate was 0% for TEM and 4.1% for anterior resection. 
These results uggest that TEM may offer some advantage relative 
to anterior esection for T1 rectal cancer, with similar oncologic 
results [11]. Our results confirm this conclusion. However, our 
series is small and nonrandomized, making larger additional pro- 
spective and randomized studies essential to confirm the true 
value of TEM for treatment of early rectal cancer [26]. 
TEM and Adjuvant Therapy 
Conservative management of rectal cancer with radiotherapy or 
endocavitary contact radiotherapy has a 30% failure rate [35]. 
Consequently, the indications for neoadjuvant or adjuvant radio- 
chemotherapy following local resection of rectal cancer by TEM 
remain controversial. In fact, local treatment of rectal cancer is 
limited by the impossibility of removing the potentially positive 
lymph node, supporting the concept of adjuvant radiotherapy, 
chemotherapy, or both to achieve local control of the lymph node 
[36]. The first published report on the combined effect of TEM 
resection for rectal cancer followed by radiotherapy appears to 
support such a benefit [18]. Recently published preliminary results 
suggest its reliability, with a 5-year recurrence-free disease sur- 
vival of 81% for irradiated patients versus 52% in those treated by 
local surgery alone [5]. However, except for T1 low grade tumors, 
there is currently a lack of evidence to recommend the use of 
TEM for curative treatment of rectal cancer, with or without 
adjuvant herapy. 
TEM and Palliative Therapy 
The use of TEM for purely palliative treatment of rectal cancer is 
not recommended [20]. In our limited experience (two cases), 
local resection of certain T2 tumors with TEM but without radio- 
therapy is viabte for compromised patients or those who refuse a 
laparotomy. However, only a few reports confirm this use of TEM, 
with a local complication rate of 14% [18, 20, 37]. Palliative 
resection of a large infiltrative tumor is discouraged by Buess 
(personal communication), because of a high local complication 
rate and the difficulty achieving hemostasis. Although local surgi- 
cal management is possible in such cases, radiochemotherapy 
should precede palliative surgical treatment and has been shown 
to facilitate surgical therapy in 83% of these patients [38]. Pre- 
liminary studies of the use of endoradiotherapy or perioperative 
radiotherapy in conjunction with local cancer resection of large 
tumors are under way [38, 39]. 
Conclusions 
Transanal endoscopic microsurgical excision of rectal tumors is 
not only an additional tool tot transanal resection of low rectal 
tumors but also a minimally invasive technique for treating minors 
in the low, middle, and upper rectum. Compared with convert- 
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tional transanal resection, TEM provides superior tumor expo- 
sure higher in the rectum (i.e., up to 18 era). The greater precision 
of resection, low morbidiV (10%, relative to anterior esection), 
and short duration of hospitalization (5 days) make this technique 
a reliable and in some cases more effective surgical approach than 
laparotomy and low anterior esection. 
With strict patient selection and precise preoperative staging, 
the use of transanal endoscopic microsurgery for treatment of low 
risk T! carcinoma is possible with a lower complication rate than 
is seen with radical surgical therapy. Preliminary results suggest 
no difference in the 5-year survival rate for local and radical 
surgical therapy. For TEM, tow risk cancer is defined as TI 
tumors with differentiation G1-G2 without lymphangiosis carei- 
nomatosa nd a resection margin of at least 5 mm in patients 
older than 45 years. However, this recommendation must be 
tempered by the lack of controlled studies to provide support. 
According to the literature and to our own surgical experience to 
date, all other types of rectal cancer should be treated by total 
mesorectal excision [10]. The contribution of adjuvant therapy to 
local treatment of rectal cancer is still under evaluation [4]. 
R~sum~ 
La mierochirurgie transanale ndoscopique (MTE) permet une 
excision locale des tumeurs itures entre 4 et 18 cm au-dessus de 
la tigne anocutanre. La technique n'est pas encore trrs rrpandue 
en raison du besoin d'une instrumentation et d'outils prcifiques, 
une technique un peu sprciale, et une srlection stricte des 
patients. Le but de cette 6tude prospective, descriptive, a 6t6 
d'analyser les indications actuelles de cette technique t d'rvaluer 
l'utilisation de ce procrd6 pour le traitement du cancer du rectum. 
En quatre ans, nous avons trait6 50 patients hgrs entre 31 et 86 
ans (fige moyen = 64 ans) par MTE pour tumeur ectale situe6 
12 cm (en moyenne) de la marge anale (extrrmes 4-18 cm). Le 
taux de complications locales a 6t6 de 4%. Soixante-six pourcent 
des 16sions 6taient bdnignes et 24% des tumeurs T1 et T2. Parmi 
les t2 eas de cancer, quatre ont nrcessit6 une rroprration pour 
excision totale du mdsorectum, les huit autres patients sont 
actuetlement sous surveillance. Pendant la prriode de suivi de 
30,6 mois (extrames = 11-54 mois), le taux de rrcidive des 
tumeurs T1 a 6t6 de 8,3%. La MTE est une technique hirurgicale 
mini-invasive qui pourrait 6tre appliqure ~ un sous-groupe de la 
population atteint de tumeur rectale. Comparre /1 ta rrsection 
transanale conventionnelle, la MTE permet une meilleure 
exposition des tumeurs du haut rectum, c'est-~-dire jusqu'/~ 18 cm 
de la marge anale. Une grande prrcision dans la rrsection, 
combin6e h une morbidit6 basse (par rapport ~ la rrsection 
antrrieure) (10%) et une eourte hospitalisation (5,5 jours) 
rendent cette technique fiable, et dans certains cas, plus efficace 
que la rrsection antrrieure par laparotomie. 
Resumen 
La microcirugfa endosc6pica transanat (TEM) permite la 
reseccidn de tumores rectales localizados de 4 a 18 cm pot encima 
dot margen anal. Este procedimiento hasta ahora no se ha 
generalizado debido a la necesidad e desarrollar instrumentos y 
herramientas e peciales, aspectos trcnicos inusuales de abordaje y 
criterios estrictos para la selecci6n de los pacientes. El objetivo de 
este estudio prospectivo y drescriptivo es analizar las indicaciones 
actualmente aceptadas para las TEM y evaluar la eficacia de esta 
tdcnica en et tratamiento dot cfincer de recto. En un periodo de 4 
afios, 50 pacientes con edades comprendidas entre 31 y 86 afios 
(media = 64 afios) fueron tratados mediante l proeedimicnto 
quirtlrgico TEM, por padecer tumores rectales ituados a 12 cm 
pot encima del margen anal (rango: 4-18 cm). La tasa de 
complicaciones locales rue del 4%. En el 76% las lesiones fueron 
benignas yen el 24% malignas: tumores T1 y T2. De los 12 casos 
de cfincer, 4 requirieron una reintervencidn con reseccidn total 
del mesorrecto; los otros 8 est~in actualmente controlados y
sometidos a tratamiento. Tras un periodo de seguimiento de 30.6 
moses (rango: 11-54 moses) la tasa de recidivas de tumores T1 rue 
deI 8.3%. La TEM es una trcnica quirdrgica mfnimamente 
invasiva que puede set may fitil en un ntimero reducido y escogido 
de pacientes con c~incer de recto. Comparada con la resecci6n 
transanal convencional, laTEM permite la exposici6n de tumores 
dot alto recto i.e. hasta 18 em de los mfirgenes del ano. La gran 
precisidn de la reseccidn, junto con la baja morbilidad (en 
comparaci6n con la reseccidn anterior) 10% y la corta 
hospitalizaci6n (5.5 d/as) hace que esta t6cniea sea, fiable y, en 
algunos casos, m~ eficaz que la laparotomia con resecci6n 
anterior baja del recto. 
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